194 related articles for article (PubMed ID: 35469393)
41. Economic Evaluation of Human Rotavirus Vaccine in Thailand.
Saokaew S; Prasitsuebsai W; Bibera GL; Kengkla K; Zhang XH; Oh KB; Lee C
Infect Dis Ther; 2019 Sep; 8(3):397-415. PubMed ID: 31197662
[TBL] [Abstract][Full Text] [Related]
42. Cost-Utility Analysis of Community Case Management for Malaria Control in Burundi.
Hezagira N; Youngkong S; Riewpaiboon A
Int J Health Policy Manag; 2022 Dec; 11(12):2990-2999. PubMed ID: 35643419
[TBL] [Abstract][Full Text] [Related]
43. Impact of vaccine herd-protection effects in cost-effectiveness analyses of childhood vaccinations. A quantitative comparative analysis.
Holubar M; Stavroulakis MC; Maldonado Y; Ioannidis JP; Contopoulos-Ioannidis D
PLoS One; 2017; 12(3):e0172414. PubMed ID: 28249046
[TBL] [Abstract][Full Text] [Related]
44. Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination.
Jit M; Edmunds WJ
Vaccine; 2007 May; 25(20):3971-9. PubMed ID: 17400341
[TBL] [Abstract][Full Text] [Related]
45. A cost effectiveness and capacity analysis for the introduction of universal rotavirus vaccination in Kenya: comparison between Rotarix and RotaTeq vaccines.
van Hoek AJ; Ngama M; Ismail A; Chuma J; Cheburet S; Mutonga D; Kamau T; Nokes DJ
PLoS One; 2012; 7(10):e47511. PubMed ID: 23115650
[TBL] [Abstract][Full Text] [Related]
46. Economic impact of a rotavirus vaccine in Brazil.
Constenla DO; Linhares AC; Rheingans RD; Antil LR; Waldman EA; da Silva LJ
J Health Popul Nutr; 2008 Dec; 26(4):388-96. PubMed ID: 19069617
[TBL] [Abstract][Full Text] [Related]
47. Cost-effectiveness analysis of diarrhoea management approaches in Nigeria: A decision analytical model.
Okafor CE; Ekwunife OI
PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006124. PubMed ID: 29261649
[TBL] [Abstract][Full Text] [Related]
48. Cost-effectiveness of rotavirus immunization in Indonesia: taking breastfeeding patterns into account.
Suwantika AA; Tu HA; Postma MJ
Vaccine; 2013 Jul; 31(32):3300-7. PubMed ID: 23707163
[TBL] [Abstract][Full Text] [Related]
49. Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030.
Atherly DE; Lewis KD; Tate J; Parashar UD; Rheingans RD
Vaccine; 2012 Apr; 30 Suppl 1():A7-14. PubMed ID: 22520139
[TBL] [Abstract][Full Text] [Related]
50. Cost-effectiveness of rotavirus vaccination in Kenya and Uganda.
Sigei C; Odaga J; Mvundura M; Madrid Y; Clark AD; ;
Vaccine; 2015 May; 33 Suppl 1():A109-18. PubMed ID: 25919149
[TBL] [Abstract][Full Text] [Related]
51. Economic evaluation of rotavirus vaccination: an important step of the introduction to the national immunization program in Thailand.
Rochanathimoke O; Riewpaiboon A; Praditsitthikorn N; Tharmaphornpilas P; Jiamsiri S; Thavorncharoensap M; Postma MJ
Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):811-819. PubMed ID: 34008471
[TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness of childhood rotavirus vaccination in Taiwan.
Wu CL; Yang YC; Huang LM; Chen KT
Vaccine; 2009 Mar; 27(10):1492-9. PubMed ID: 19186200
[TBL] [Abstract][Full Text] [Related]
53. Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries.
Tu HA; Rozenbaum MH; Coyte PC; Li SC; Woerdenbag HJ; Postma MJ
Vaccine; 2012 Feb; 30(8):1521-8. PubMed ID: 22119590
[TBL] [Abstract][Full Text] [Related]
54. Using QALYs versus DALYs to measure cost-effectiveness: How much does it matter?
Feng X; Kim DD; Cohen JT; Neumann PJ; Ollendorf DA
Int J Technol Assess Health Care; 2020 Apr; 36(2):96-103. PubMed ID: 32340631
[TBL] [Abstract][Full Text] [Related]
55. Impact of transmission dynamics on the cost-effectiveness of rotavirus vaccination.
Shim E; Galvani AP
Vaccine; 2009 Jun; 27(30):4025-30. PubMed ID: 19389452
[TBL] [Abstract][Full Text] [Related]
56. Potential impact and cost-effectiveness analysis of rotavirus vaccination of children in Israel.
Chodick G; Waisbourd-Zinman O; Shalev V; Kokia E; Rabinovich M; Ashkenazi S
Eur J Public Health; 2009 Jun; 19(3):254-9. PubMed ID: 19221026
[TBL] [Abstract][Full Text] [Related]
57. Health impact and cost-effectiveness of a domestically-produced rotavirus vaccine in India: A model based analysis.
Rose J; Homa L; Meropol SB; Debanne SM; Bielefeld R; Hoyen C; Singer ME
PLoS One; 2017; 12(11):e0187446. PubMed ID: 29099848
[TBL] [Abstract][Full Text] [Related]
58. Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland.
Tilson L; Jit M; Schmitz S; Walsh C; Garvey P; McKeown P; Barry M
Vaccine; 2011 Oct; 29(43):7463-73. PubMed ID: 21821085
[TBL] [Abstract][Full Text] [Related]
59. Potential epidemiological and economical impact of two rotavirus vaccines in Colombia.
De la Hoz F; Alvis N; Narváez J; Cediel N; Gamboa O; Velandia M
Vaccine; 2010 May; 28(22):3856-64. PubMed ID: 20347057
[TBL] [Abstract][Full Text] [Related]
60. Achieving malaria testing and treatment targets for children under five in Mozambique: a cost-effectiveness analysis.
Avanceña ALV; Miller A; Canana N; Dula J; Saifodine A; Cadrinho B; Maffioli EM
Malar J; 2022 Nov; 21(1):320. PubMed ID: 36344998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
